683 Capital Management, LLC Protagonist Therapeutics, Inc Transaction History
683 Capital Management, LLC
- $1.4 Billion
- Q4 2024
A detailed history of 683 Capital Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, 683 Capital Management, LLC holds 410,000 shares of PTGX stock, worth $15.9 Million. This represents 1.13% of its overall portfolio holdings.
Number of Shares
410,000
Previous 420,000
2.38%
Holding current value
$15.9 Million
Previous $18.9 Million
16.15%
% of portfolio
1.13%
Previous 1.72%
Shares
9 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$230 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$223 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$213 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$164 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$129 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.9B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...